CD274 and neoplasm: Available reports indicate that PD-L1 expression on tumor-infiltrating lymphocytes before the start of treatment appears to confer better survival (132, 133) and response to trastuzumab-containing therapy (28), but only one study describes downregulation of PD-L1+ TIL after neoadjuvant chemotherapy (NAC) with trastuzumab, with no clear association with clinical response (28).